X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (262) 262
Book Review (34) 34
Patent (34) 34
Newspaper Article (33) 33
Conference Proceeding (21) 21
Publication (16) 16
Dissertation (12) 12
Magazine Article (10) 10
Book / eBook (6) 6
Reference (6) 6
Book Chapter (3) 3
Trade Publication Article (2) 2
Web Resource (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (134) 134
humans (125) 125
oncology (103) 103
female (97) 97
breast cancer (59) 59
breast neoplasms - drug therapy (53) 53
trastuzumab (43) 43
breast neoplasms - pathology (42) 42
middle aged (40) 40
animals (39) 39
adult (32) 32
breast neoplasms - metabolism (32) 32
performing operations (32) 32
transporting (32) 32
cancer (31) 31
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
aged (28) 28
chemotherapy (28) 28
antibodies, monoclonal, humanized (27) 27
mice (27) 27
producing particular articles from plastics or from substancesin a plastic state (26) 26
working of plastics (26) 26
working of substances in a plastic state, in general (26) 26
antineoplastic agents - therapeutic use (25) 25
physics (25) 25
care and treatment (24) 24
optics (24) 24
receptor, erbb-2 - metabolism (24) 24
medicine & public health (23) 23
antibodies, monoclonal - therapeutic use (20) 20
breast neoplasms - genetics (20) 20
research (20) 20
expression (19) 19
monoclonal-antibody (19) 19
treatment outcome (19) 19
ovarian-cancer (18) 18
analysis (17) 17
male (17) 17
therapy (17) 17
antibodies, monoclonal - administration & dosage (16) 16
cell line, tumor (16) 16
contact lenses (16) 16
spectacles (16) 16
sunglasses or goggles insofar as they have the same featuresas spectacles (16) 16
survival (16) 16
tumors (16) 16
antineoplastic agents - pharmacology (15) 15
disease-free survival (15) 15
antibodies, monoclonal - pharmacology (14) 14
health aspects (14) 14
paper (14) 14
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
article (13) 13
drug therapy (13) 13
neoplasm staging (13) 13
receptor, erbb-2 - analysis (13) 13
receptor, erbb-2 - genetics (13) 13
tumor cells, cultured (13) 13
dyeing leather, furs, or solid macromolecular substances inany form (12) 12
dyeing or printing textiles (12) 12
flexible materials not otherwise provided for (12) 12
laundering (12) 12
metastasis (12) 12
mice, nude (12) 12
neoplasm metastasis (12) 12
textiles (12) 12
treatment of textiles or the like (12) 12
aged, 80 and over (11) 11
breast neoplasms - therapy (11) 11
growth-factor receptor (11) 11
immunotherapy (11) 11
in-situ hybridization (11) 11
optical elements, systems, or apparatus (11) 11
prognosis (11) 11
survival analysis (11) 11
antineoplastic combined chemotherapy protocols - pharmacology (10) 10
breast neoplasms - chemistry (10) 10
breast neoplasms - mortality (10) 10
cell biology (10) 10
clinical trials as topic (10) 10
dose-response relationship, drug (10) 10
gene expression regulation, neoplastic (10) 10
her2 (10) 10
mutation (10) 10
phase-ii trial (10) 10
receptor (10) 10
receptor, erbb-2 - immunology (10) 10
breast-cancer (9) 9
ovarian neoplasms - pathology (9) 9
phase-ii (9) 9
receptor, erbb-2 - antagonists & inhibitors (9) 9
taxoids - administration & dosage (9) 9
abridged index medicus (8) 8
amplification (8) 8
biochemistry & molecular biology (8) 8
cancer therapies (8) 8
docetaxel (8) 8
drug resistance (8) 8
gene amplification (8) 8
genetics & heredity (8) 8
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (4) 4
Online Resources - Online (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Law (Bora Laskin) - Stacks (1) 1
Music - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Koboldt, Daniel C and Fulton, Robert S and McLellan, Michael D and Schmidt, Heather and Kalicki-Veizer, Joelle and McMichael, Joshua F and Fulton, Lucinda L and Dooling, David J and Ding, Li and Mardis, Elaine R and Wilson, Richard K and Ally, Adrian and Balasundaram, Miruna and Butterfield, Yaron S. N and Carlsen, Rebecca and Carter, Candace and Chu, Andy and Chuah, Eric and Chun, Hye-Jung E and Coope, Robin J. N and Dhalla, Noreen and Guin, Ranabir and Hirst, Carrie and Hirst, Martin and Holt, Robert A and Lee, Darlene and Li, Haiyan I and Mayo, Michael and Moore, Richard A and Mungall, Andrew J and Pleasance, Erin and Robertson, A. Gordon and Schein, Jacqueline E and Shafiei, Arash and Sipahimalani, Payal and Slobodan, Jared R and Stoll, Dominik and Tam, Angela and Thiessen, Nina and Varhol, Richard J and Wye, Natasja and Zeng, Thomas and Zhao, Yongjun and Birol, Inanc and Jones, Steven J. M and Marra, Marco A and Cherniack, Andrew D and Saksena, Gordon and Onofrio, Robert C and Pho, Nam H and Carter, Scott L and Schumacher, Steven E and Tabak, Barbara and Hernandez, Bryan and Gentry, Jeff and Nguyen, Huy and Crenshaw, Andrew and Ardlie, Kristin and Beroukhim, Rameen and Winckler, Wendy and Getz, Gad and Gabriel, Stacey B and Meyerson, Matthew and Chin, Lynda and Kucherlapati, Raju and Hoadley, Katherine A and Auman, J. Todd and Fan, Cheng and Turman, Yidi J and Shi, Yan and Li, Ling and Topal, Michael D and He, Xiaping and Chao, Hann-Hsiang and Prat, Aleix and Silva, Grace O and Iglesia, Michael D and Zhao, Wei and Usary, Jerry and Berg, Jonathan S and Adams, Michael and Booker, Jessica and Wu, Junyuan and Gulabani, Anisha and Bodenheimer, Tom and Hoyle, Alan P and Simons, Janae V and Soloway, Matthew G and Mose, Lisle E and Jefferys, Stuart R and Balu, Saianand and Parker, Joel S and Hayes, D. Neil and Perou, Charles M and Malik, Simeen and Mahurkar, Swapna and Shen, Hui and Weisenberger, Daniel J and Triche Jr, Timothy and Lai, Phillip H and ... and Canc Genome Atlas Network and Cancer Genome Atlas Network and The Cancer Genome Atlas Network
Nature, ISSN 0028-0836, 10/2012, Volume 490, Issue 7418, pp. 61 - 70
We analysed primary breast cancers by genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and... 
PATHWAYS | TARGET | BASAL-LIKE | SUPPRESSOR | PIK3CA GENE | SUBTYPES | MULTIDISCIPLINARY SCIENCES | HIGH-FREQUENCY | LUMINAL-B | CANCER | MUTATIONAL EVOLUTION | GATA3 Transcription Factor - genetics | Receptors, Estrogen - metabolism | Oligonucleotide Array Sequence Analysis | Genomics | Humans | Gene Expression Regulation, Neoplastic | Ovarian Neoplasms - pathology | Gene Expression Profiling | Breast Neoplasms - metabolism | Ovarian Neoplasms - genetics | DNA Methylation | DNA Mutational Analysis | Female | Genes, BRCA1 | Genes, Neoplasm - genetics | Breast Neoplasms - classification | RNA, Messenger - genetics | Retinoblastoma Protein - metabolism | DNA Copy Number Variations - genetics | Genes, p53 - genetics | Mutation - genetics | Genetic Heterogeneity | Genome, Human - genetics | Phosphatidylinositol 3-Kinases - genetics | Exome - genetics | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Breast Neoplasms - pathology | Retinoblastoma Protein - genetics | Genes, erbB-2 - genetics | Proteomics | Protein Array Analysis | RNA, Neoplasm - genetics | MAP Kinase Kinase Kinase 1 - genetics | MicroRNAs - genetics | Breast tumors | Gene mutations | Oncology, Experimental | Genetic aspects | Research | Identification and classification | Cancer | Proteins | DNA methylation | Genetics | Breast cancer | Mutation | Index Medicus | Càncer de mama | Oncologia | Oncology | Gene expression | Expressió gènica | Genòmica
Journal Article
by Lundqvist, Andreas and van Hoef, Vincent and Zhang, Xiaonan and Wennerberg, Erik and Lorent, Julie and Witt, Kristina and Sanz, Laia Masvidal and Liang, Shuo and Murray, Shannon and Larsson, Ola and Kiessling, Rolf and Mao, Yumeng and Sidhom, John-William and Bessell, Catherine A and Havel, Jonathan and Schneck, Jonathan and Chan, Timothy A and Sachsenmeier, Eliot and Woods, David and Berglund, Anders and Ramakrishnan, Rupal and Sodre, Andressa and Weber, Jeffrey and Zappasodi, Roberta and Li, Yanyun and Qi, Jingjing and Wong, Philip and Sirard, Cynthia and Postow, Michael and Newman, Walter and Koon, Henry and Velcheti, Vamsidhar and Callahan, Margaret K and Wolchok, Jedd D and Merghoub, Taha and Lum, Lawrence G and Choi, Minsig and Thakur, Archana and Deol, Abhinav and Dyson, Gregory and Shields, Anthony and Haymaker, Cara and Uemura, Marc and Murthy, Ravi and James, Marihella and Wang, Daqing and Brevard, Julie and Monaghan, Catherine and Swann, Suzanne and Geib, James and Cornfeld, Mark and Chunduru, Srinivas and Agrawal, Sudhir and Yee, Cassian and Wargo, Jennifer and Patel, Sapna P and Amaria, Rodabe and Tawbi, Hussein and Glitza, Isabella and Woodman, Scott and Hwu, Wen-Jen and Davies, Michael A and Hwu, Patrick and Overwijk, Willem W and Bernatchez, Chantale and Diab, Adi and Massarelli, Erminia and Segal, Neil H and Ribrag, Vincent and Melero, Ignacio and Gangadhar, Tara C and Urba, Walter and Schadendorf, Dirk and Ferris, Robert L and Houot, Roch and Morschhauser, Franck and Logan, Theodore and Luke, Jason J and Sharfman, William and Barlesi, Fabrice and Ott, Patrick A and Mansi, Laura and Kummar, Shivaani and Salles, Gilles and Carpio, Cecilia and Meier, Roland and Krishnan, Suba and McDonald, Dan and Maurer, Matthew and Gu, Xuemin and Neely, Jaclyn and Suryawanshi, Satyendra and Levy, Ronald and Khushalani, Nikhil and Wu, Jennifer and Zhang, Jinyu and Basher, Fahmin and Rubinstein, Mark and Bucsek, Mark and Qiao, Guanxi and ...
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 11/2016, Volume 4, Issue S1
Journal Article
Blood, ISSN 0006-4971, 11/2011, Volume 118, Issue 18, pp. 4817 - 4828
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 732 - 742
Summary Background The antibody–drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer... 
Hematology, Oncology and Palliative Medicine | RECEPTOR | ONCOLOGY | PERTUZUMAB | DOCETAXEL | GUIDELINES | Capecitabine - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Response Evaluation Criteria in Solid Tumors | Antineoplastic Agents - therapeutic use | Hand-Foot Syndrome - etiology | Diarrhea - chemically induced | Young Adult | Breast Neoplasms - chemistry | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Lapatinib | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Trastuzumab - administration & dosage | Breast Neoplasms, Male - drug therapy | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Breast Neoplasms, Male - chemistry | Disease-Free Survival | Retreatment | Taxoids - administration & dosage | Vomiting - chemically induced | Aspartate Aminotransferases - blood | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - adverse effects | Aged | Breast Neoplasms, Male - pathology | Receptor, ErbB-2 - analysis | Bridged-Ring Compounds - administration & dosage | Care and treatment | Breast cancer | Metastasis | Patient outcomes | Analysis | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 19, pp. 1783 - 1791
Women with metastatic breast cancer that had progressed during treatment with trastuzumab plus a taxane were assigned to lapatinib plus capecitabine or to... 
CAPECITABINE | LAPATINIB | MEDICINE, GENERAL & INTERNAL | THERAPY | PHASE-II | ANTIBODY | RECEPTOR | PLUS | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Young Adult | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Fluorouracil - analogs & derivatives | Maytansine - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Survival Rate | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 - analysis | Deoxycytidine - analogs & derivatives | Trastuzumab | Drugs | Dose-response relationship (Biochemistry) | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Comparative analysis | Thrombocytopenia | Chemotherapy | Epidermal growth factor | Vomiting | Diarrhea | Cytotoxicity | Nausea | Survival | ErbB-2 protein | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5538 - 5546
Purpose Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial... 
EFFICACY | ONCOLOGY | RANDOMIZED PHASE-II | TAMOXIFEN RESISTANCE | GROWTH | MCF-7 CELLS | COMBINATION | INHIBITOR | EXPRESSION | ESTROGEN-RECEPTOR | PLUS | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2004, Volume 96, Issue 10, pp. 739 - 749
Background. Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers... 
TUMOR-CELL LINES | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | IN-VITRO | PACLITAXEL TAXOL(R) | ONCOLOGY | 1ST-LINE CHEMOTHERAPY | RANDOMIZED-TRIAL | MONOCLONAL-ANTIBODY | CLINICAL PHARMACOKINETICS | DOCETAXEL TAXOTERE(R) | Up-Regulation | Cyclophosphamide - analogs & derivatives | Paclitaxel - pharmacology | Taxoids - pharmacology | Neoplastic Stem Cells - drug effects | Humans | Receptor, ErbB-2 - metabolism | Deoxycytidine - pharmacology | Transplantation, Heterologous | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Vinblastine - analogs & derivatives | Female | Gene Expression Regulation, Neoplastic - drug effects | Receptor, ErbB-2 - drug effects | Disease Models, Animal | Floxuridine - pharmacology | Cell Survival - drug effects | Tumor Stem Cell Assay | Proto-Oncogene Proteins - drug effects | Enzyme-Linked Immunosorbent Assay | Antibodies, Monoclonal - pharmacology | Docetaxel | Breast Neoplasms - drug therapy | DNA, Neoplasm - drug effects | Guanine Nucleotide Exchange Factors | Drug Synergism | Animals | Mice, Nude | Cyclophosphamide - pharmacology | Cell Line, Tumor | Mice | Vinblastine - pharmacology | Carboplatin - pharmacology | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology | Trastuzumab | Vinorelbine | Epirubicin - pharmacology | Chemotherapy | Care and treatment | Breast cancer | Research | Health aspects | Drug therapy | Medical treatment | Index Medicus
Journal Article